Dose model for stent-based delivery of a radioactive compound for the treatment of restenosis in coronary arteries

Medical Physics

Volumn 30, Issue 10, 2003, Pages 2622-2628

  Janicki, Christian ^a   Hwang, Chao Wei ^b   Edelman, Elazer R ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dosimetry; Oligonucleotide; Pharmacokinetics; Radiolabeled drugs; Restenosis; Stents

Indexed keywords

ARTIFICIAL ORGANS; BINDING ENERGY; CARDIOVASCULAR SYSTEM; CONTROLLED DRUG DELIVERY; CONVOLUTION; DISEASES; DOSIMETRY; DRUG DOSAGE; FUNCTIONAL POLYMERS; HISTOLOGY; HYDROPHILICITY; OLIGONUCLEOTIDES; PHARMACOKINETICS; RADIATION; RADIOACTIVITY; RAPID TRANSIT; RESIDENCE TIME DISTRIBUTION; STENTS; TISSUE;

ACTIVITY DISTRIBUTION; DRUG DELIVERY DEVICES; HYDROPHILIC COMPOUNDS; INTERNAL RADIATION DOSE; NON-UNIFORM RADIATIONS; RADIOACTIVE COMPOUNDS; RADIOLABELED DRUGS; RESTENOSIS;

TARGETED DRUG DELIVERY;

OLIGONUCLEOTIDE; PHOSPHORUS 32; POLYMER; RADIOACTIVE MATERIAL;

ACCURACY; ARTERY WALL; ARTICLE; CORONARY STENT; DIFFUSION; DOSIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TRANSPORT; HUMAN; HYDROPHILICITY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RESTENOSIS;

ANIMALIA;

EID: 0142025635     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1607506     Document Type: Article

References (26)

1. P. S. Teirstein and R. E. Kuntz, "New frontiers in interventional cardiology: Intravascular radiation to prevent restenosis," Circulation 104, 2620-2626 (2001).
2. L. Gruberg and R. Waksman, "Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries," Expert Opin. Investg. Drugs 10, 891-907 (2001).
3. R. A. Fox, "Intravascular brachytherapy of the coronary arteries," Phys. Med. Biol. 47, R1-R30 (2002).
4. 188 Re-filled balloon system during intracoronary brachytherapy: A case report," Cardio. Rad. Med. 2, 7-10 (2000).
5. 32P radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff," Circulation 104, 2236-2241 (2001).
6. R. Fattori and T. Piva, "Drug-eluting stents in vascular intervention," Lancet 361, 247-249 (2003).
7. J. Fareh, R. Martel, and G. Leclerc, "Feasibility, safety and dosimetry of intramural administration of 32-P-oligonucleotide-mediating beta-particle delivery to prevent restenosis," Cardio. Rad. Med. 2, 7-10 (2000).
8. W. E. Bolch et al., The Dosimetry of Non-Uniform Activity Distributions-Adionuclide S values at the Voxel Level, MIRD Pamphlet No. 17, Society of Nuclear Medicine, New York, 1999 [J. Nucl. Med. 40, 11S-36S (1999)].
9. W. E. Bolch et al., The Dosimetry of Non-Uniform Activity Distributions-Adionuclide S values at the Voxel Level, MIRD Pamphlet No. 17, Society of Nuclear Medicine, New York, 1999 [J. Nucl. Med. 40, 11S-36S (1999)].
10. W. G. Cross, N. O. Freedman, and P. Y. Wong, "Tables of beta-ray dose distributions in water," Report AECL-10521, Atomic Energy of Canada Limited, Chalk River, Ontario, 1992.
11. M. J. Berger, "Energy deposition in water by photons from point isotropic sources," MIRD Pamphlet No. 2, Society of Nuclear Medicine, New York, 1968.
12. NCRP, National Council on Radiation Protection and Measurements, "Conceptual basis for calculations of absorbed-dose distributions," NCRP Report No. 108, National Council on Radiation Protection and Measurements, Bethesda, MD, 1991.
13. MATLAB, 1992, MATLAB Reference Guide, The Math Works, Inc., Natick, MA.
14. M. A. Lovich and E. R. Edelman, "Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery," Circ. Res. 77, 1143-1150 (1995).
15. M. A. Lovich and E. R. Edelman, "Tissue average binding and equilibrium distribution: An example with heparin in arterial tissues," Biophys. J. 70, 1553-1559 (1996).
16. O. Elmalak, M. A. Lovich, and E. Edelman, "Correlation of transarterial transport of various dextrans with their physicochemical properties," Biomaterials 21, 2263-2272 (2000).
17. C. W. Hwang, D. Wu, and E. R. Edelman, "Physiological transport forces govern drug distribution for stent-based delivery," Circulation 104, 600-605 (2001).
18. C. Janicki, D. M. Duggan, C. W. Coffey II, D. R. Fischell, and T. A. Fischell, "Radiation dose from a Phosphorous-32 impregnated wire mesh vascular stent," Med. Phys. 24, 437-445 (1997).
19. A. L. Lewis and T. A. Vick, "Site-specific drug delivery from coronary stents," Drug Delivery Systems and Sciences 1, 65-71 (2001).
20. F. Gobeil, G. Leclerc, R. Martel, M. Bouchard, M. Laflamme, P. St-Jacques, and J. Fareh, "Pharmacokinetic of a stent based local drug delivery of a short DNA oligonucleotide coupled with P32 (OLIGLOW) in a swine model," Canadian Cardiovascular Congress, 20-24 October, 2001, Halifax, Nova Scotia (abstract).
21. M. K. Dewanjee, A. K. Ghafouripour, M. Kapadvanjwala, S. Dewanjee, A. N. Serafini, D. M. Lopez, and G. N. Sfakianakis, "Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary mmor-bearing mouse model," J. Nucl. Med. 35, 1054-1063 (1994).
22. A. S. Kirschner, R. D. Ice, and W. H. Beierwaltes, "Radiation dosimetry of 1311-19-iodocholesterol," J. Nucl. Med. 14, 713-717 (1973).
23. H. J. Motulsky, "Analyzing data with GraphPad Prism," GraphPad Software Inc., San Diego CA, www.graphpad.com.
24. M. G. Stabin, "MIRDOSE: A personal computer software for internal dose assessment in nuclear medicine," J. Nucl. Med. 37, 538-546 (1996).
25. H.-P. Stoll, K, Carlson, L. K. Keefer, J. A. Hrabie, and K. L. March, "Pharmacokinetics and consistency of pericardial delivery directed coronary arteries: Direct comparison with endolumial delivery," Clin. Cardiol. 22(Suppl I), I-10-I-16 (1999).
26. H. C. Lowe, S. N. Oesterle, and L. M. Khachigian, "Coronary in-stent restenosis: Current status and future strategies," J. Am. Coll. Cardiol. 39, 183-193 (2002).